Company intelligence / Profile preview

Recardio Inc.

San Francisco, California, United Statesrecardio.eu ↗

Ownership: Private
Development stage: Phase 3

Overview

Recardio’s lead candidate, Dutogliptin, has completed Phase 2 trials demonstrating an excellent safety profile and potential positive effects on cardiac function. The FDA and EMA have agreed to the design of a pivotal global Phase 3 trial (“HEAL-MI”) evaluating Dutogliptin with filgrastim in early recovery post-myocardial infarction. The trial will enroll approximately 4,000 patients globally across the US, Europe, and China. Other pipeline programs are at preclinical stages.[2][3][5]

Therapeutic areas: OtherCardiovascular
Modalities: Small molecules (notably DPP-IV inhibitors)
Industry: Biotech

Drug pipeline

1 asset

dutogliptin

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed.

Beyond the preview

Go deeper on Recardio Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Recardio Inc..

Explore the full profile